Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178).
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2013
At a glance
- Drugs Mirabegron; Rifampicin
- Indications Overactive bladder; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma US
- 03 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 12 Nov 2008 New trial record.